Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 470-474    https://doi.org/10.1007/s11684-009-0077-7
Research articles
Preliminary results of gentamycin combined with sodium bicarbonate for prevention of irinotecan-induced diarrhea
Qi MEI MM1,Zhe CAO MM1,Hua XIONG MD1,Yuan CHEN MD2,
1.The Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2.;
 Download: PDF(92 KB)  
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract The aim of this paper was to observe the clinical effect of gentamycin combined with sodium bicarbonate for the prevention of irinotecan-induced diarrhea. A total of 98 patients with stage IV cancers were recruited and divided into a prevention group (52 patients) and a control group (46 patients). All patients received the chemotherapy including irinotecan. The prevention group received gentamycin and sodium bicarbonate before the use of irinotecan for 4 days; the control group did not receive any prevention. The use of gentamycin and sodium bicarbonate resulted in significantly higher stool pH (P < 0.001), while the incidence of diarrhea by irinotecan was reduced (prevention group 13.70% versus control group 34.83%; P < 0.001). Gentamycin combined with sodium bicarbonate appears to be useful in preventing the diarrhea induced by irinotecan and reducing the dosage of loperamide and fluid replacement.
Keywords irinotecan      diarrhea      gentamycin      sodium bicarbonate      prevention      
Issue Date: 05 December 2009
 Cite this article:   
Qi MEI MM,Hua XIONG MD,Zhe CAO MM, et al. Preliminary results of gentamycin combined with sodium bicarbonate for prevention of irinotecan-induced diarrhea[J]. Front. Med., 2009, 3(4): 470-474.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0077-7
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/470
Boku N. GastrointestinalOncology Study Group of Japan Clinical Oncology Group. Chemotherapyfor metastatic disease: review from JCOG trials. Int J Clin Oncol, 2008, 13(3): 196―200

doi: 10.1007/s10147-008-0784-0
Maeda Y, Ohune T, Nakamura M, Yamasaki M, Kiribayashi Y, Murakami T. Prevention of irinotecan-induced diarrhoea by oral carbonaceousadsorbent (Kremezin) in cancer patients. Oncol Rep, 2004, 12(3): 581―585
Yang X, Hu Z, Chan S Y, Goh B C, Duan W, Chan E, Zhou S. Simultaneous determinationof the lactone and carboxylate forms of irinotecan (CPT-11) and itsactive metabolite SN-38 by high-performance liquid chromatography:application to plasma pharmacokinetic studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 821(2): 221―228

doi: 10.1016/j.jchromb.2005.05.010
Hahn K K, Wolff J J, Kolesar J M. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm, 2006, 63(22): 2211―2217

doi: 10.2146/ajhp060155
Humerickhouse R, Lohrbach K, Li L, Bosron W F, Dolan M E. Characterization of CPT-11hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res, 2000, 60(5): 1189―1192
Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the activemetabolite of irinotecan. Ann Oncol, 1998, 9(8): 845―847

doi: 10.1023/A:1008438109725
Iyer L, Hall D, Das S, Mortell M A, Ramírez J, Kim S, Di Rienzo A, Ratain M J. Phenotype-genotype correlationof in vitro SN-38 (active metabolite of irinotecan) and bilirubinglucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther1999, 65(5): 576―582

doi: 10.1016/S0009-9236(99)70078-0
de Jong F A, de Jonge M J, Verweij J, Mathijssen R H. Role of pharmacogenetics in irinotecan therapy. Cancer Lett, 2006, 234(1): 90―106

doi: 10.1016/j.canlet.2005.04.040
Mathijssen R H, van Alphen R J, Verweij J, Loos W J, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokineticsand metabolism of irinotecan (CPT-11). Clin Cancer Res, 2001, 7(8): 2182―2194
Iyer L, King C D, Whitington P F, Green M D, Roy S K, Tephly T R, Coffman B L, Ratain M J. Genetic predisposition to the metabolism of irinotecan(CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform1A1 in the glucuronidation of its active metabolite (SN-38) in humanliver microsomes. J Clin Invest, 1998, 101(4): 847―854

doi: 10.1172/JCI915
Kehrer D F, Sparreboom A, Verweij J, de Bruijn P, Nierop C A, van de Schraaf J, Ruijgrok E J, de Jonge M J. Modulation of irinotecan-induceddiarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res, 2001, 7(5): 1136―1141
Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B. Intestinal alkalization asa possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res, 2002, 62(1): 179―187
Fassberg J, Stella V J. A kinetic and mechanisticstudy of the hydrolysis of camptothecin and some analogues. J Pharm Sci, 1992, 81(7): 676―684

doi: 10.1002/jps.2600810718
de Jong F A, Kehrer D F, Mathijssen R H, Creemers G J, de Bruijn P, van Schaik R H, Planting A S, van der Gaast A, Eskens F A, Janssen J T, Ruit J B, Verweij J, Sparreboom A, de Jonge M J. Prophylaxis of irinotecan-induceddiarrhea with neomycin and potential role for UGT1A1*28 genotype screening:a double-blind, randomized, placebo-controlled study. Oncologist, 2006, 11(8): 944―954

doi: 10.1634/theoncologist.11-8-944
[1] Solmaz Ohadian Moghadam, Seyed Ali Momeni. Human microbiome and prostate cancer development: current insights into the prevention and treatment[J]. Front. Med., 2021, 15(1): 11-32.
[2] Cenyi Shao, Shijian Li, Feng Zhu, Dahai Zhao, Hui Shao, Haixiao Chen, Zhiruo Zhang. Taizhou’s COVID-19 prevention and control experience with telemedicine features[J]. Front. Med., 2020, 14(4): 506-510.
[3] Eun Young Lee, Kun-Ho Yoon. Epidemic obesity in children and adolescents: risk factors and prevention[J]. Front. Med., 2018, 12(6): 658-666.
[4] Yanyan Jiang, Zhongying Yuan, Guoqing Zang, Dan Li, Ying Wang, Yi Zhang, Hua Liu, Jianping Cao, Yujuan Shen. Cyclospora cayetanensis infections among diarrheal outpatients in Shanghai: a retrospective case study[J]. Front. Med., 2018, 12(1): 98-103.
[5] Qingmeng Zhang, Fengmin Zhang, Baofeng Yang. Pneumonic plague epidemic in Northeast China in 1910–1911: Dr. Wu Lien-Teh’s epidemic preventive system for plague control[J]. Front. Med., 2018, 12(1): 113-115.
[6] Yang Sun,Chenze Li,Lina Zhang,Dong Hu,Xudong Zhang,Ting Yu,Min Tao,Dao Wen Wang,Xiaoqing Shen. Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients[J]. Front. Med., 2017, 11(1): 53-61.
[7] Chunsong Hu,Qinghua Wu. Health: a dream from reality to the future[J]. Front. Med., 2016, 10(2): 233-235.
[8] Yi Cao. Environmental pollution and DNA methylation: carcinogenesis, clinical significance, and practical applications[J]. Front. Med., 2015, 9(3): 261-274.
[9] Rui Yu,Rong Fan,Jinlin Hou. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China[J]. Front. Med., 2014, 8(2): 135-144.
[10] James S. Park,Calvin Pan. Current recommendations of managing HBV infection in preconception or pregnancy[J]. Front. Med., 2014, 8(2): 158-165.
[11] Jin Gao, Ben Panizza, Newell W. Johnson, Scott Coman, Alan R. Clough. Basic consideration of research strategies for head and neck cancer[J]. Front Med, 2012, 6(4): 339-353.
[12] Marie-Germaine Bousser. Stroke prevention: an update[J]. Front Med, 2012, 6(1): 22-34.
[13] Yiling Wu. Construction of the vessel-collateral theory and its guidance for prevention and treatment of vasculopathy[J]. Front Med, 2011, 5(2): 118-122.
[14] Shi-Ming CHENG MD, Yu-Ji LAI MS, Er-Yong LIU MS, Lin ZHOU MD, Xue-Jing WANG MS, Qiu-Lan CHEN MS, Dong-Ming LI MS, Ning WANG MD, . Study on factors affecting TB/HIV co-infection in four counties of China[J]. Front. Med., 2010, 4(2): 185-191.
[15] Jun-Jie XIAO MD, Yi-Han CHEN MD, PhD, . Prevalence of cardiovascular diseases in China[J]. Front. Med., 2010, 4(1): 16-20.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed